Porównanie podskórnej i dożylnej immunoglobuliny u pacjentów z przewlekłą zapalną polineuropatią demielinizacyjną (CIDP) bez wcześniejszego leczenia

Chronic inflammatory demyelinating polyneuropathy, known as CIDP, is a condition that affects the nerves, leading to weakness and numbness. This study is focused on comparing two treatments for CIDP: Hizentra and Privigen. Both treatments contain a substance called human normal immunoglobulin, which is a protein derived from blood that helps the immune system. Hizentra is given as a subcutaneous injection, meaning it is injected under the skin, while Privigen is administered as an intravenous infusion, meaning it is given directly into a vein.

The purpose of the study is to evaluate the effects of these two treatments in patients who have not previously received treatment for CIDP. The study will last for 26 weeks, during which participants will receive either Hizentra or Privigen. The study will assess changes in the participants' ability to perform daily activities and their overall disability level. This will be measured using a questionnaire that tracks changes from the beginning to the end of the study period.

Participants will be monitored for changes in muscle strength, sensory abilities, and overall functional ability. Additional assessments will include tests for quality of life, pain levels, and satisfaction with the treatment. Blood samples will be taken to measure levels of certain proteins and blood cells. The study aims to determine which treatment is more effective in managing the symptoms of CIDP and improving the quality of life for patients.